by Scott Harwood | Aug 9, 2024
Hideki Garren, MD, PhD, Chief Medical Officer for Prothena, discusses the pathophysiology of AL amyloidosis and the mechanism of action of investigational drug birtamimab. Amyloid light chain (AL) amyloidosis is a progressive plasma cell disorder in...
by Scott Harwood | Aug 6, 2024
Alaa Hamed, Global Head of Medical Affairs for Rare Diseases for Sanofi, discusses two clinical trials that reinforce positive data for hemophilia treatments. Hemophilia is a rare bleeding disorder that slows the blood clotting process. People with this...
by Scott Harwood | Jul 31, 2024
Fadi Fakhouri, MD, PhD, Professor of Nephrology at Lausanne University, discusses the results from a phase 2 clinical trial testing the safety and efficacy of pegcetacoplan in patients with C3G and IC-MPGN. Complement 3 glomerulopathy (C3G) and...
by Scott Harwood | Oct 25, 2023
The U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is...
by Scott Harwood | Oct 25, 2023
Joseph Mikhael, MD, Chief Medical Officer at the International Myeloma Foundation talks about the M-POWER program. Transcription: At the International Myeloma Foundation, it’s a privilege for me to work there, one of the greatest...
